← 返回

分泌型 DKK3 对肝癌患者循环 CD56(bright) NK 细胞的影响

英文原题:Effect of secretory DKK3 on circulating CD56(bright) natural killer cells in patients with liver cancer.

查看英文原题

Effect of secretory DKK3 on circulating CD56(bright) natural killer cells in patients with liver cancer.

PubMed 2023/04/18(内容时间) Int J Biol Markers Q3 · IF 2.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

通过 DKK3 提高 NK 细胞的临床疗效将成为癌症免疫治疗的新策略。

中文摘要

肝癌威胁人类健康。自然杀伤(NK)细胞是先天免疫系统重要组成,抗肿瘤能力强,基于NK细胞的肝癌免疫治疗已成为研究热点。

研究以ELISA和流式细胞术分别检测肝癌患者血清DKK3(sDKK3)和循环CD56 bright NK细胞,并体外分析重组人DKK3对CD56 bright NK细胞的作用。

肝癌患者sDKK3水平较低,且与循环CD56 bright NK细胞呈负相关。研究首次发现DKK3可诱导CD56 bright NK细胞分化并增强其细胞毒性,因此可能作为NK细胞免疫疗法的激动剂。

通过DKK3提升NK细胞临床疗效,可能成为癌症免疫治疗新策略。

展开英文摘要原文

Liver cancer seriously threatens human health. Natural killer (NK) cells are an important part of the innate immune system and have strong anti-tumor ability. Immunotherapy based on NK cells has become a hot topic in the treatment of liver cancer.

In this study, we checked the serum DKK3 (sDKK3) and circulating CD56 bright NK cells using ELISA and flow cytometry, respectively, in the blood of liver cancer patients. The effect on recombinant human DKK3 (rhDKK3) on CD56 bright NK cells was analyzed in vitro.

We found low levels of sDKK3 in liver cancer patients and a negative correlation between sDKK3 and circulating CD56 bright NK cells. In addition, we found that DKK3 induced the differentiation and improved the cytotoxicity of CD56 bright NK cells for the first time. It could be used as an agonist for NK cell-based immunotherapy.

Improving the clinical efficacy of NK cells through DKK3 will become a new strategy for cancer immunotherapy.

论文信息

作者
Liu DH、Wen GM、Song CL、Xia P
单位
Biological Anthropology Institute, College of Basic Medical Science, Jinzhou Medical University, Jinzhou, Liaoning, P.R. China.China
期刊
The International journal of biological markers2023 Jun
原文标识
PubMed 37071578 · DOI 10.1177/03936155231169796